ESC Premium Access

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study

Congress Presentation

About the speaker

Professor Juha Hartikainen

Kuopio University Hospital, Kuopio (Finland)
4 presentations
0 follower

8 more presentations in this session

Oral anticoagulants in patients with atrial fibrillation having an intermediate risk of ischemic stroke but a high risk of bleeding

Speaker: Doctor T. Chao (Taipei, TW)


Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study

Speaker: Doctor P. Rasmussen (Copenhagen, DK)


Age-dependent anti-thrombotic therapy for atrial fibrillation patients with intermediate risk (CHA2DS2-VASc Score of 1 or 2) of ischemic stroke

Speaker: Associate Professor S. Choi (Daegu, KR)


Mortality in patients with non-valvular atrial fibrillation in South America. Warfarin has significant higher global mortality rates versus dabigatran and rivaroxaban

Speaker: Doctor G. Vanerio (Montevideo, UY)


Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease

Speaker: Doctor C. Coleman (Storrs, US)


Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

Speakers: Professor J. Hartikainen, Doctor T. Chao, Doctor P. Rasmussen, Associate Professor S. Choi, Doctor G. Vanerio...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb